EU case definition for diarrhoea and haemolytic uremic syndrome (HUS) caused by the epidemic strain Shiga toxin 2-producing Escherichia Coli (STEC) O104:H4
Public health advice on prevention of diarrhoeal illness with special focus on Shiga toxin - producing Escherichia coli (STEC), also called verotoxin - producing E. coli (VTEC) or enterohaemorrhagic E. coli (EHEC)
Outbreak of Shiga toxin - producing Escherichia coli (STEC), also called verotoxin-producing E. coli (VTEC) or enterohaemorrhagic E. coli (EHEC) in 2011
In EU, only 1 in every 3 MDR TB patients has a successful treatment outcome; more than half either die, fail treatment or default (stop taking treatment). XDR TB has even worse treatment outcomes: only 1 in 4 patients finishes treatment successfully.
Supplementary Web Appendices for Tuberculosis in hard-to-reach populations 1: Barriers and facilitators to the uptake of tuberculosis diagnostic and treatment services by hard-to-reach populations in countries of low and medium tuberculosis incidence: a systematic review of qualitative literature
Tuberculosis (TB) has become the world’s leading single infectious disease killer, an unenviable title previously held by HIV/AIDS. It is therefore more important than ever to join forces against TB to successfully reach the goal of ending TB by 2030.
Chlamydia infection, campylobacteriosis, salmonellosis, gonorrhoea and tuberculosis were the most commonly reported notifiable infectious diseases in the EU and EEA in 2014.
New data released by the European Centre for Disease Prevention and Control (ECDC) and WHO/Europe ahead of World TB Day show that an estimated 340 000 Europeans developed tuberculosis (TB) in 2014, corresponding to a rate of 37 cases per 100 000 population.